Jacobs Solutions enters the final stretch before its August 4 earnings date with short sellers quietly rebuilding positions even as the stock trades near a one-month high — a mild but noteworthy tension worth tracking.
The short interest story has shifted modestly since last week's note. Shorts had been anchored around 5.8% of free float for months, but the position has edged up to 6.0% of free float over the past month, with a 3% week-on-week increase bringing shares short to roughly 7.14 million. That's not an aggressive rebuild — it's a grind higher, not a conviction-driven pile-in. The borrow market remains completely untroubled by it. Availability has actually loosened further, now running above 1,130% — meaning there are more than eleven times as many shares available to borrow as there are currently shorted. Cost to borrow slipped another 9% on the week to just 0.37%, a multi-month low. Nothing in the lending market signals any squeeze risk or institutional urgency to get short. The options market remains firmly call-skewed: the put/call ratio is 0.16, just below its 20-day average of 0.17, and still near the lower end of a 52-week range where the high was 1.58. Hedging demand has not returned despite the creeping short interest. Overall, positioning reads as mildly more cautious on the short side, but far too loose in the borrow market to constitute a crowded or pressured setup.
The Street reflects the same constructive-but-selective tone. The consensus tilts bullish — Citi has a Buy with a $181 target, RBC holds Outperform at $169, and Goldman, which initiated coverage in late 2025, sits at Buy with a $158 target. Against a current price of $129.26, the mean analyst target of $156.40 implies roughly 21% upside. The bears have a case: Wells Fargo trimmed to $131 in May, barely above the current price, and Truist cut its Hold target another dollar to $149 as recently as July 2. That cluster of Hold-side trimming after the May earnings print — when the stock fell 3% the next day and shed 12.7% over the following five sessions — reflects lingering skepticism about near-term execution through the Amentum spin complexity and labor cost pressure. Factor scores reinforce the split: the dividend score ranks in the 96th percentile, but the short score at 24 and the DTC rank at 18 both flag that the short-side positioning is relatively light rather than punishing. Valuation is undemanding, with the P/E near 15.7x and EV/EBITDA at 11.4x — modest for an engineering services firm with AI infrastructure and life sciences tailwinds in its order book.
The insider activity from two months ago adds a useful data point for context. CEO Bob Pragada bought 3,601 shares at $111.09 in mid-May — a $400,000 purchase — shortly after the stock's post-earnings slide. The stock has since recovered about 16% from those levels to the current $129.26, suggesting the trade has worked. There has been no follow-through buying since, and the CFO ran a small sale in June, keeping the 90-day net insider position modestly positive at just over $700,000 in value terms. BlackRock added 864,780 shares in the most recent quarterly filing, lifting its stake to 8.9% — the largest single institutional move in the holder table and a meaningful show of support at a time when several sell-side names were trimming targets.
The earnings reaction history is the sharpest thing to keep in mind going forward. The May print produced a 3.2% one-day loss and a 12.7% five-day decline — a substantial post-earnings drawdown. With the next report due August 4 and the stock now 16% above those post-earnings lows, the setup heading into that date will matter considerably more than it did heading into May. The degree to which short interest continues to rebuild between now and early August — and whether options traders abandon their current call-skew — is the clearest signal worth monitoring.
See the live data behind this article on ORTEX.
Open J on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
